Biobot Analytics
MIT-alumni founded startup (2017, $91.5M total funding across 15 rounds, ~$20M annual revenue) running the national Biobot Portal; awarded the White House ONDCP contract in January 2026 to deliver nationwide substance-use intelligence across more than 20 chemical targets, building on its 2020–2024 NIDA SBIR programme.
- Country
- United States
us
ondcp
platform
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Wastewater-based epidemiology | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.